¼¼°èÀÇ ³úÀÚµµ ½ÃÀå : ½ÃÀå ±Ô¸ð¿Í ±âȸ ºÐ¼® - ¼ºÀå Àü·«, °æÀï, ¿¹Ãø(2025-2032³â)
Magnetoencephalography Market Size & Opportunities Analysis - Growth Strategies, Competitiveness, and Forecasts (2025 - 2032)
»óǰÄÚµå : 1803328
¸®¼­Ä¡»ç : Prescient & Strategic Intelligence
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 300 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,900 £Ü 6,876,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,400 £Ü 8,981,000
Printable PDF (Group User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,400 £Ü 11,788,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

³úÀÚµµ(MEG) ½ÃÀå ±Ô¸ð´Â 2024³â 3¾ï 790¸¸ ´Þ·¯¿¡¼­ 2032³â 4¾ï 7,070¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö 5.6%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº MEG ±â¼úÀÇ ¹ßÀü, ½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡, ºñħ½ÀÀû Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ½Å°æ¼¼Æ÷ÀÇ È°µ¿¿¡ ÀÇÇØ ¹ß»ýÇÏ´Â ÀÚ±âÀåÀ» ÃøÁ¤ÇÏ´Â °í°¨µµ ±â¼úÀÎ MEG´Â °£Áú, ³úÁ¾¾ç, Ä¡¸Å, ±âŸ ½Å°æÁúȯ µîÀÇ »óŸ¦ Áø´ÜÇÏ´Â ºñħ½ÀÀûÀÎ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ½ÃÀåÀº °í·ÉÈ­ Àα¸ÀÇ Áõ°¡¿Í Á¶±â Áø´Ü ¹× Á¶±â °³ÀÔ¿¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇØ ´õ¿í µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀü, ƯÈ÷ ¼¾¼­ÀÇ ¼ÒÇüÈ­, È޴뼺, µ¥ÀÌÅÍ ºÐ¼®À» À§ÇÑ ÀΰøÁö´É(AI) ¹× ¸Ó½Å·¯´×°úÀÇ ÅëÇÕÀ¸·Î MEG ½Ã½ºÅÛÀº ´õ¿í Ä£¼÷Çϰí Á¤È®ÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ½Å°æ°úÇп¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸ ±â°ü»Ó¸¸ ¾Æ´Ï¶ó ƯÈ÷ ÀÓ»ó ÇöÀå¿¡¼­ MEGÀÇ Àû¿ë ¹üÀ§¸¦ È®ÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºñħ½ÀÀû °Ë»ç ¹æ¹ý¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö°í ³ú °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ MEG Àåºñ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

±â¼úÀÇ ¹ßÀü - ±¤Àڷ°è(OPM)¸¦ ±â¹ÝÀ¸·Î ÇÑ MEG ½Ã½ºÅÛÀº ³·Àº ¿î¿µºñ¿ë, Çâ»óµÈ °¨µµ, È޴뼺À¸·Î ÀÎÇØ ±Þ°ÝÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ±âÁ¸ÀÇ ÃÊÀüµµ ¾çÀÚ °£¼· ¼ÒÀÚ(SQUID)¿Í ´Þ¸®, OPM ±â¹Ý ½Ã½ºÅÛÀº °ú³Ã°¢ÀÌ ÇÊ¿äÇÏÁö ¾Ê±â ¶§¹®¿¡ º¸´Ù ÄÄÆÑÆ®ÇÏ°í ºñ¿ë È¿À²ÀûÀÌ¸ç ¸ð¹ÙÀÏ ¹× ¿þ¾î·¯ºí ¾ÖÇø®ÄÉÀ̼ǿ¡ ÀûÇÕÇÕ´Ï´Ù.

°£Áú, Ä¡¸Å, ³úÁ¹Áß°ú °°Àº ½Å°æÁúȯÀÇ À¯º´·ü Áõ°¡´Â MEG ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, 2030³â±îÁö °£Áú ȯÀÚ ¼ö´Â 7,800¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, Ä¡¸Å ȯÀÚµµ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. MEGÀÇ ³ôÀº °ø°£Àû, ½Ã°£Àû ÇØ»óµµ·Î ºñÁ¤»óÀûÀÎ ³ú Ȱµ¿À» °¨ÁöÇÏ´Â ´É·ÂÀº Á¶±â Áø´Ü ¹× Ä¡·á °èȹÀ» À§ÇÑ ±ÍÁßÇÑ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù.

ÀÓ»ó ÀÀ¿ë - ÀÓ»ó ºÐ¾ß´Â °£Áú, Ä¡¸Å, Á¤½ÅºÐ¿­Áõ µî Á¤¹Ð Áø´ÜÀÇ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó 2024³â 65%ÀÇ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ƯÈ÷ °£ÁúÀº ¹ßÀÛ º´¼Ò¸¦ Á¤È®ÇÏ°Ô ÆÄ¾ÇÇÒ ¼ö ÀÖ°í, ȯÀÚÀÇ ¼ö¼ú ¼ºÀûÀ» Çâ»ó½Ãų ¼ö ÀÖ¾î MEGÀÇ °¡Àå Áß¿äÇÑ ¿ëµµ Áß ÇϳªÀÔ´Ï´Ù.

¿¬±¸ ¿ëµµ - ¿¬±¸ ºÐ¾ß´Â ³úÀÇ ±â´É°ú Àå¾Ö¸¦ ÀÌÇØÇÏ´Â µ¥ ÁßÁ¡À» µÎ°í Àֱ⠶§¹®¿¡ °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¬±¸±â°üµéÀº ³ú°áÇÕ, ÀÎÁö±â´É, ½Å°æÁ¤½ÅÁúȯÀÇ µ¿¿ªÇÐÀ» ¿¬±¸Çϱâ À§ÇØ MEG¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ÀÇ BRAIN Initiative¿Í À¯·´ÀÇ Human Brain Project´Â MEG¿Í °°Àº ºñħ½ÀÀû ¿µ»ó µµ±¸¸¦ ÇÊ¿ä·Î ÇÏ´Â ¿¬±¸¸¦ Áö¿øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ Ãß¼¼¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚ ¿ªÇÐ - º´¿øÀº ¿©ÀüÈ÷ MEG ½Ã½ºÅÛÀÇ °¡Àå Å« ÃÖÁ¾»ç¿ëÀÚ·Î 2024³â ½ÃÀå Á¡À¯À²ÀÇ 45%¸¦ Â÷ÁöÇÕ´Ï´Ù. º´¿ø¿¡¼­ÀÇ MEG µµÀÔÀº ½Å°æ°ú¿¡¼­ °íµµÀÇ Áø´Ü ´É·Â¿¡ ´ëÇÑ Çʿ伺¿¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ½Å°æ°úÇÐ ¿¬±¸ ¹× ÀÓ»ó½ÃÇè¿¡ MEG ±â¼úÀ» äÅÃÇÏ´Â ¿¬±¸±â°üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Çмú ¹× ¿¬±¸±â°ü ºÎ¹®ÀÌ °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áö¿ªº° ¼ºÀå - ºÏ¹Ì°¡ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²(40%)À» Â÷ÁöÇßÀ¸¸ç, ¹Ì±¹ÀÌ Â÷¼¼´ë MEG ½Ã½ºÅÛ Ã¤ÅÃÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº °¡Ã³ºÐ ¼ÒµæÀÌ ³ô°í, ÀÇ·á ÀÎÇÁ¶ó°¡ ¹ß´ÞµÇ¾î ÀÖÀ¸¸ç, ÀÇÇÐ ¿¬±¸¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÏ¹Ì¿¡¼­´Â MEG¿¡ ´ëÇÑ »óȯ Á¤Ã¥¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ¾î MEGÀÇ Ã¤ÅÃÀÌ ´õ¿í ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁøÀÔÀ庮°ú ½ÃÀå °æÀï - MEG ½ÃÀåÀº ÅëÇյǾî ÀÖÀ¸¸ç, Compumedics Limited, MEGIN, GE Healthcare, Philips Healthcare¿Í °°Àº ¼Ò¼öÀÇ ÁÖ¿ä ±â¾÷ÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. MEG ½Ã½ºÅÛ °³¹ß ºñ¿ëÀÌ ³ô°í, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ °úÁ¤°ú ±â¼úÀÇ º¹À⼺ÀÌ ´õÇØÁ® ½Å±Ô ÁøÀÔ¿¡ Å« À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¼¾¼­ ±â¼úÀÇ ¹ßÀü°ú AI¸¦ žÀçÇÑ MEG ½Ã½ºÅÛÀÇ µîÀåÀº ±â¼ú Çõ½Å°ú ½ÃÀå È®´ëÀÇ ±âȸ¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù.

ÆÄÆ®³Ê½Ê°ú Çù¾÷ - MEG ½ÃÀåÀÇ ¼ºÀåÀ» À§Çؼ­´Â Çаè, »ê¾÷°è, Á¤ºÎ±â°üÀÇ Çù·ÂÀÌ ÇʼöÀûÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, MEGINÀÇ FIND Neuro¿ÍÀÇ Á¦ÈÞ¿Í Â÷¼¼´ë ½Å°æ¿µ»ó ±â¼ú °³¹ßÀ» À§ÇÑ Àεµ Á¤ºÎÀÇ ÀÚ±Ý Áö¿øÀº MEGÀÇ ÀÓ»ó ¹× ¿¬±¸ Àû¿ëÀ» ÃËÁøÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°èÀÇ ³úÀÚµµ(EEG) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°, ±¹°¡º° µ¿Çâ°ú ½ÃÀå¿¡ ÁøÃâÇÑ ±â¾÷ °³¿ä µîÀ» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ÁöÇ¥

Á¦5Àå ¾÷°è Àü¸Á

Á¦6Àå °æÀï ±¸µµ

Á¦7Àå ¼¼°è ½ÃÀå

Á¦8Àå ºÏ¹Ì ½ÃÀå

Á¦9Àå À¯·´ ½ÃÀå

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦11Àå ¶óÆ¾¾Æ¸Þ¸®Ä« ½ÃÀå

Á¦12Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦13Àå ¹Ì±¹ ½ÃÀå

Á¦14Àå ij³ª´Ù ½ÃÀå

Á¦15Àå ¿µ±¹ ½ÃÀå

Á¦16Àå µ¶ÀÏ ½ÃÀå

Á¦17Àå ÇÁ¶û½º ½ÃÀå

Á¦18Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦19Àå ½ºÆäÀÎ ½ÃÀå

Á¦20Àå Áß±¹ ½ÃÀå

Á¦21Àå ÀϺ» ½ÃÀå

Á¦22Àå È£ÁÖ ½ÃÀå

Á¦23Àå Àεµ ½ÃÀå

Á¦24Àå Çѱ¹ ½ÃÀå

Á¦25Àå ºê¶óÁú ½ÃÀå

Á¦26Àå ¸ß½ÃÄÚ ½ÃÀå

Á¦27Àå UAE ½ÃÀå

Á¦28Àå »ç¿ìµð¾Æ¶óºñ¾Æ ½ÃÀå

Á¦29Àå ³²¾ÆÇÁ¸®Ä«°øÈ­±¹ ½ÃÀå

Á¦30Àå ±â¾÷ °³¿ä

Á¦31Àå ºÎ·Ï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The magnetoencephalography (MEG) market is anticipated to grow from USD 307.9 million in 2024 to USD 470.7 million by 2032, progressing at a CAGR of 5.6% from 2025 to 2032. This growth is largely driven by advancements in MEG technologies, the increasing prevalence of neurological disorders, and the growing demand for non-invasive diagnostic tools. MEG, a highly sensitive technique for measuring the magnetic fields generated by neuronal activity, offers a non-invasive method for diagnosing conditions such as epilepsy, brain tumors, dementia, and other neurological disorders. The market is further supported by the rising aging population and a greater focus on early diagnosis and intervention.

Technological advancements, particularly in sensor miniaturization, portability, and integration with artificial intelligence (AI) and machine learning for data analysis, have made MEG systems more accessible and accurate. These innovations have expanded the scope of MEG applications, particularly in clinical settings, as well as research institutions focused on neuroscience. Furthermore, the increasing preference for non-invasive testing methods and the growing awareness of brain health issues have also contributed to the rising demand for MEG devices.

Key Insights

Technological Advancements: MEG systems based on optically pumped magnetometers (OPMs) are expected to experience the fastest growth due to their lower operating costs, enhanced sensitivity, and portability. Unlike traditional superconducting quantum interference devices (SQUIDs), OPM-based systems do not require supercooling, making them more compact, cost-effective, and adaptable for mobile and wearable applications.

Rising Prevalence of Neurological Disorders: The increasing global burden of neurological disorders such as epilepsy, dementia, and stroke is one of the major growth drivers for the MEG market. According to the World Health Organization, the number of people affected by epilepsy is expected to rise to 78 million by 2030, while dementia cases are anticipated to increase significantly. MEG's ability to detect abnormal brain activity with high spatial and temporal resolution makes it a valuable tool for early diagnosis and treatment planning.

Clinical Applications: The clinical segment dominated the market with a 65% share in 2024, driven by the growing need for precise diagnostics in conditions such as epilepsy, dementia, and schizophrenia. Epilepsy, in particular, is one of the most significant applications of MEG, as it allows for the accurate identification of seizure foci, improving surgical outcomes for patients.

Research Applications: The research segment is expected to grow at the highest CAGR due to the increasing focus on understanding brain functions and disorders. Research institutions are investing in MEG to study brain connectivity, cognitive functions, and the dynamics of neuropsychiatric disorders. The U.S. BRAIN Initiative and the European Human Brain Project are fueling this trend by supporting research that requires non-invasive imaging tools like MEG.

End-User Dynamics: Hospitals remain the largest end-user of MEG systems, accounting for 45% of the market share in 2024. The adoption of MEG in hospitals is driven by the need for advanced diagnostic capabilities in neurology departments. However, the academic and research institutes segment is expected to grow the fastest, as more research institutions are adopting MEG technology for neuroscience studies and clinical trials.

Regional Growth: North America holds the largest market share (40%) in 2024, with the U.S. leading the adoption of next-generation MEG systems. The region's high disposable income, advanced healthcare infrastructure, and significant investments in medical research contribute to the growth of the market. Additionally, the increasing focus on reimbursement policies for MEG in North America is expected to further drive its adoption.

Barriers to Entry and Market Competition: The MEG market is consolidated, with a few key players, such as Compumedics Limited, MEGIN, GE Healthcare, and Philips Healthcare, leading the market. The high cost of developing MEG systems, combined with regulatory approval processes and technological complexity, creates significant barriers for new entrants. However, advancements in sensor technology and the rise of AI-powered MEG systems present opportunities for innovation and market expansion.

Partnerships and Collaborations: Collaboration between academia, industry, and government bodies is crucial for the growth of the MEG market. For instance, MEGIN's partnership with FIND Neuro and the funding from the Indian government for the development of next-gen neuroimaging technologies are expected to advance MEG's clinical and research applications.

Table of Contents

Chapter 1. Research Scope

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

Chapter 6. Competitive Landscape

Chapter 7. Global Market

Chapter 8. North America Market

Chapter 9. Europe Market

Chapter 10. Asia-Pacific Market

Chapter 11. Latin America Market

Chapter 12. Middle East & Africa Market

Chapter 13. U.S. Market

Chapter 14. Canada Market

Chapter 15. U.K. Market

Chapter 16. Germany Market

Chapter 17. France Market

Chapter 18. Italy Market

Chapter 19. Spain Market

Chapter 20. China Market

Chapter 21. Japan Market

Chapter 22. Australia Market

Chapter 23. India Market

Chapter 24. South Korea Market

Chapter 25. Brazil Market

Chapter 26. Mexico Market

Chapter 27. U.A.E. Market

Chapter 28. Saudi Arabia Market

Chapter 29. South Africa Market

Chapter 30. Company Profiles

Chapter 31. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â